Compare Duolingo Inc (DUOL) vs Hims and Hers Health Inc (HIMS) Price & Performance

Duolingo (DUOL) trades at $151.72, up 2.42% with a bullish technical signal. The stock shows strong fundamentals with revenue growth from $369M in 2022 to $1.04B in 2025 and net income surging to $414M. Recent earnings consistently beat expectations, though Q3 2026 results are pending. Analyst consensus is mixed with 37.5% buy ratings but a $140.63 price target below current levels. Operating cash flow reached $388M in 2025, supporting continued investment in user growth and AI capabilities.

Duolingo presents growth potential through AI-driven expansion and strong user metrics, but faces risks from insider selling and valuation concerns. The stock's current price exceeds analyst consensus, suggesting limited near-term upside. Key opportunities include market expansion beyond language learning, while risks involve competitive pressures and execution on monetization strategies.

Hims & Hers Health trades at $29.54, up slightly by 0.24% on the day. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company reported revenue of $2.35 billion in 2025 but swung to a net loss of $142 million in 2026, with a negative net margin of 5.51%. Analyst consensus is a 'Hold' with a price target of $32.17, but the stock faces significant headwinds from multiple securities class action lawsuits announced in early October 2026.

The outlook for HIMS is clouded by legal risks and profitability challenges despite revenue growth. Investment opportunity hinges on the company's ability to return to profitability and resolve regulatory scrutiny. Key risks include ongoing litigation, FTC complaints, and execution missteps in a competitive telehealth market. Wall Street remains cautious with 65% of analysts recommending Hold.